Evaluation and treatment of children and adolescents with psychotic symptoms

Current Psychiatry Reports

Volumn 14, Issue 2, 2012, Pages 101-110

  Algon, Sibel ^b   Yi, James ^b   Calkins, Monica E ^c   Kohler, Christian ^c   Borgmann Winter, Karin E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adolescents; At risk; Children; Prodrome; Psychosis; Psychotic symptoms; Schizophrenia; Ultra high risk (UHR); Youth

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIS; CYCLOSERINE; GLYCINE; GUANFACINE; HERBACEOUS AGENT; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; OPIATE DERIVATIVE; PLACEBO; PSYCHEDELIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; ANXIETY DISORDER; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; CHROMOSOME DISORDER; CLINICAL EVALUATION; COGNITIVE REHABILITATION; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGENITAL DISORDER; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG ABUSE; DRUG DOSE TITRATION; DSM-5; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; FAMILY THERAPY; GASTROINTESTINAL SYMPTOM; HIGH RISK BEHAVIOR; HUMAN; INFECTION; LOOSE FECES; LOW DRUG DOSE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; NAUSEA; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OCCUPATIONAL THERAPY; ONSET AGE; PATHOGENESIS; POSITIVE SYNDROME; PRACTICE GUIDELINE; PREVALENCE; PSYCHOSIS; REVIEW; SCHEDULE FOR AFFECTIVE DISORDERS AND SCHIZOPHRENIA; SCHIZOPHRENIA; SIDE EFFECT; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYMPTOMATOLOGY; TREATMENT RESPONSE; WEIGHT GAIN; ADOLESCENT; CHILD; FEMALE; MALE; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RISK FACTOR; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL SUPPORT;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; COGNITIVE THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL SUPPORT;

EID: 84860624954     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0258-y     Document Type: Review

References (74)

1. Gearing, R. E. Evidence-based family psychoeducational interventions for children and adolescents with psychotic disorders. J Can Acad Child Adolesc Psychiatry. 2008;17(1).
2. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179-208. In this systematic review, the authors offer a comprehensive overview of available literature on pharmacologic interventions for childhood-onset schizophrenia. The authors summarize limitations in several aspects of current pharmacotherapy, including low effect size, high rates of adverse effects, and low rates of remission. They highlight the need for further research with both randomized, placebo-controlled studies and long-term, naturalistic follow-up of large samples of patients with different age ranges.
3. Simon AE, et al. Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res. 2006;81(1):83-90. (Pubitemid 41817209)
4. Miller TJ, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-5. (Pubitemid 34465065)
5. Klosterkotter J, et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158-64. (Pubitemid 32142753)
6. Miller TJ, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-15. (Pubitemid 38181951)
7. Borgmann-Winter K, et al. Assessment of adolescents at risk for psychosis. Curr Psychiatry Rep. 2006;8(4):313-21. (Pubitemid 44227239)
8. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry. 1998;155(3):325-36. (Pubitemid 28114888)
9. Lax Pericall MT, Taylor E. Psychosis and epilepsy in young people. Epilepsy Behav. 2010;18(4):450-4.
10. Yu HH, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus. 2006;15(10):651-7.
11. Bismilla Z, Sell E, Donner E. Hashimoto encephalopathy responding to risperidone. J Child Neurol. 2007;22(7):855-7. (Pubitemid 47261238)
12. Arrojo M, et al. Psychiatric presentation of Hashimoto's encephalopathy. Psychosom Med. 2007;69(2):200-1. (Pubitemid 46667988)
13. Benvenga S, Lapa D, Trimarchi F. Don't forget the thyroid in the etiology of psychoses. Am J Med. 2003;115(2):159-60. (Pubitemid 37288850)
14. Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091.
15. Florance NR, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11.
16. Fenton KA. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007;45:S213.
17. Maling S, et al. HIV-1 seroprevalence and risk factors for HIV infection among first-time psychiatric admissions in Uganda. AIDS Care. 2011;23(2):171-8.
18. Scharko AM. DSM psychiatric disorders in the context of pediatric HIV/AIDS. AIDS Care. 2006;18(5):441-5.
19. Misdrahi D, et al. DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1). Eur Psychiatry. 2004;19(3):182-4. (Pubitemid 38670462)
20. Carman JS, Wyatt RJ. Calcium: pacesetting the periodic psychoses. Am J Psychiatry. 1979;136(8):1035-9. (Pubitemid 9221647)
21. Ang AW, Ko SM, Tan CH. Calcium, magnesium, and psychotic symptoms in a girl with idiopathic hypoparathyroidism. Psychosom Med. 1995;57(3):299-302.
22. Hershko C, et al. Lead poisoning in a West Bank Arab Village. Arch Intern Med. 1984;144(10):1969-73. (Pubitemid 14021030)
23. McCracken JT. Lead intoxication psychosis in an adolescent. J Am Acad Child Adolesc Psychiatry. 1987;26(2):274-6. (Pubitemid 17040976)
24. Hancu A, Mihai MC, Axelerad AD. Wilson's disease: a challenging diagnosis. Clinical manifestations and diagnostic procedures in 12 patients. Rev Med Chir Soc Med Nat Iasi. 2011;115(1):58-63.
25. Dening TR, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. Arch Gen Psychiatry. 1989;46(12):1126-34. (Pubitemid 20016451)
26. Rahman A, et al. Zinc, manganese, calcium, copper, and cadmium level in scalp hair samples of schizophrenic patients. Biol Trace Elem Res. 2009;127(2):102-8.
27. Lauterbach MD, Stanislawski-Zygaj AL, Benjamin S. The differential diagnosis of childhood-and young adult-onset disorders that include psychosis. J Neuropsychiatry Clin Neurosci. 2008;20(4):409.
28. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-41, HHS Publication No. (SMA) 11-4658, S. A.a. M. H. S. Administration, Editor. 2011: Rockville, MD.
29. Veen ND, et al. Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004;161(3):501-6. (Pubitemid 38326105)
30. Dragt S, et al. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012;125(1):45-53.
31. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196-204. (Pubitemid 39208220)
32. Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465-88.
33. Young CM, Findling RL. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother. 2004;4(1):53-60. (Pubitemid 38082123)
34. AACAP official action. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1580-2.
35. Lubman DI, et al. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. Acta Psychiatr Scand. 2002;106:331.
36. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA. 1999;282(1):36-9. (Pubitemid 29318930)
37. Freudenreich O, et al. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. Harv Rev Psychiatry. 2007;15(5):189-211. (Pubitemid 47557206)
38. Arseneault L, et al. Childhood trauma and children's emerging psychotic symptoms: a genetically sensitive longitudinal cohort study. Am J Psychiatry. 2011;168(1):65-72.
39. Mazzoni P, et al. Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis. J Child Adolesc Psychopharmacol. 2009;19(6):771-6.
40. Meyer SE, et al. The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. J Child Adolesc Psychopharmacol. 2005;15(3):434-51. (Pubitemid 41192830)
41. Velthorst E, et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res. 2009;109(1-3):60-5.
42. Woods SW, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study.[see comment]. Schizophr Bull. 2009;35(5):894-908.
43. Pavuluri M, Herbener E, Sweeney J. Psychotic symptoms in pediatric bipolar disorder. J Affect Disord. 2004;80:19-28. (Pubitemid 38496525)
44. Ulloa RE, et al. Psychosis in a pediatric mood and anxiety disorders clinic: phenomenology and correlates. J Am Acad Child Adolesc Psychiatry. 2000;39(3):337-45. (Pubitemid 30127613)
45. Calderoni D, et al. Differentiating childhood-onset schizophrenia from psychotic mood disorders. J Am Acad Child Adolesc Psychiatry. 2001;40(10):1190-6. (Pubitemid 32917085)
46. Biederman J, et al. Phenomenology of childhood psychosis: findings from a large sample of psychiatrically referred youth. J Nerv Ment Dis. 2004;192(9):607-14. (Pubitemid 39238408)
47. Norman RM, et al. The role of treatment delay in predicting 5-year outcomes in an early intervention program. Psychol Med. 2011; (Journal Article): 1-11.
48. Lappin JM, et al. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res. 2007;95(1-3):103-10. (Pubitemid 47313637)
49. Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-804. (Pubitemid 41428609)
50. Malla AK, et al. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res. 2011;125(1):13-20.
51. McGorry PD, et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206-12.
52. Simon AE, et al. Ultra high-risk state for psychosis and nontransition: a systematic review. Schizophr Res. 2011;132(1):8-17. This systematic review summarizes available literature on outcomes of those identified as UHR. A total of 31 studies met the inclusion criteria, and on average, 76% (range, 46%-92.6%) of UHR patients made no transition to psychosis during a follow-up period (range, 6-40 months). Characteristics of those who did not transition were poorly investigated. The authors highlight the limited specificity of current UHR criteria and the need for more studies investigating the characteristics associated with nontransition versus transition.
53. Filakovic P, et al. Ethics of the early intervention in the treatment of schizophrenia. Psychiatr Danub. 2007;19(3):209-15. (Pubitemid 47521148)
54. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res. 2001;51(1):47-54. (Pubitemid 32722068)
55. Rabinovitch MB-EL, et al. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28.
56. de Koning MB, et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand. 2009;119(6):426-42. In this paper, early interventions in patients at UHR for psychosis are reviewed. The authors compiled preliminary publications and unpublished data from the German Research Network on Schizophrenia. Patients from the Bechdolf et al. [58] (2007) cohort who received CBT were found less likely to convert to psychosis or develop a late prodromal state at 1-year follow-up than those who received supportive counseling.
57. Addington J, et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54-61.
58. Bechdolf A, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry. 2007;1(1):71-8.
59. French P, et al. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. Br J Psychiatry Suppl. 2007;51:s82-7. (Pubitemid 350273194)
60. Poon MY, Siu AM, Ming SY. Outcome analysis of occupational therapy programme for persons with early psychosis. Work. 2010;37(1):65-70.
61. Rietdijk J, et al. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials. 2010;11:30.
62. Yung AR, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis:6-month analysis. J Clin Psychiatry. 2011;72(4):430-40. The authors conducted a randomized controlled trial in youth at UHR for psychosis comparing CTplus low-dose risperidone with CT supportive counseling, and a monitoring control condition. All treatment groups had improvements in measures of psychosis and depression, and no differences were found among groups. Declining transition rates, inadequate power, transition post-study, andaplacebo effect in the monitoring control condition may explain these findings.
63. Morrison AP, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004;185:291-7. (Pubitemid 39331330)
64. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009;17(4):291-4.
65. Compton MT, et al. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophr Res. 2011;126(1-3):71-6.
66. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother. 2010;10(8):1347-59.
67. Liu P, et al. An evidence map of interventions across premorbid, ultra-high risk and first episode phases of psychosis. Schizophr Res. 2010;123(1):37-44. The authors generated an evidence map of controlled trials, meta-analysis, and systematic reviews of biologic and psychosocial interventions in premorbid, UHR, and first-episode patients with psychosis. Most studies in this population involved firstepisode patients, antipsychotic medication trials, and CBT trials. The authors concluded that trials of biologic interventions, other than antipsychotics and psychosocial treatments other than CBT, are lacking and are needed in these patients.
68. McGlashan TH, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-9. (Pubitemid 44464525)
69. McGorry PD, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921-8.
70. Cornblatt BA, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546-57. (Pubitemid 46663037)
71. Amminger GP, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-54. The utility of omega-3 PUFAs to diminish the progression of high-risk youth with subthreshold psychotic symptoms to first-episode psychosis was explored in the randomized, placebo-controlled trial. The authors concluded that long-chain omega-3 PUFAs reduce the risk of transition to psychotic disorders and are a safe and welltolerated prevention strategy in youth with subthreshold psychotic symptoms.
72. Woods SW, et al. Glycine treatment of prodromal symptoms, Abstracts of the 5th International Conference on Early Psychosis. Schizophr Res. 2006;86(WC2E):S7.
73. Liu CC, et al. Rapid response to antipsychotic treatment on psychotic prodrome: implications from a case series. Psychiatry Clin Neurosci. 2010;64(2):202-6.
74. Woods SW, et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl. 2007;51:s96-s101. (Pubitemid 350273196)